Gyre Therapeutics (GYRE) Cash from Investing Activities (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Cash from Investing Activities data on file, last reported at -$3.1 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$3.1 million, down 255.31% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.5 million (up 48.62% YoY), and the FY2025 annual result was -$474000.0, up 97.62% from the prior year.
• Cash from Investing Activities slipped to -$3.1 million in Q1 2026 per GYRE's latest filing, from $1.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $52.9 million in Q2 2022 and troughed at -$69.2 million in Q4 2022.
• A 5-year average of -$3.6 million and a median of -$2.7 million in 2024 frame the typical range for Cash from Investing Activities.
• On a YoY basis, Cash from Investing Activities climbed as much as 393.94% in 2022 and fell as far as 2514.13% in 2022.
• A 5-year view of Cash from Investing Activities shows it stood at -$69.2 million in 2022, then jumped by 101.94% to $1.3 million in 2023, then plunged by 249.66% to -$2.0 million in 2024, then soared by 192.22% to $1.8 million in 2025, then plunged by 265.31% to -$3.1 million in 2026.
• Business Quant data shows GYRE's Cash from Investing Activities at -$3.1 million in Q1 2026, $1.8 million in Q4 2025, and -$1.2 million in Q3 2025.